Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

Blood research·2026

Same author

Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.

Leukemia·2026

Same author

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Blood·2026

Same author

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

Haematologica·2026

Same author

Thromboembolic Events after Surgery for Localized Prostate Cancer: Incidence, Risk Factors, and Survival Outcomes.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026

Same author

Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts.

Annals of hematology·2026

Search research articles

Related Experiment Video

Updated: Aug 8, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Practical issues in CAR T-cell therapy.

¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

|February 27, 2023

Summary

Chimeric antigen receptor (CAR) T-cell therapy engineers a patient's T-cells to fight cancer. This review examines the challenges hindering effective CAR T-cell therapy in Korea.

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T-cell therapy is a personalized approach to cancer treatment.
This therapy involves genetically modifying a patient's T-cells to target tumor antigens.
CAR T-cells are expanded and reinfused to attack cancer cells, representing a significant advancement in immunotherapy.

Purpose of the Study:

To review the current state of CAR T-cell therapy.
To identify and discuss the barriers to effective CAR T-cell therapy implementation.
To focus on the specific challenges within the Korean healthcare landscape.

Main Methods:

Literature review of existing studies on CAR T-cell therapy.
Analysis of clinical trial data and regulatory frameworks.

Keywords:

Barrier CAR T-cell therapy Korea Patient access

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Aug 8, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Discussion of challenges based on scientific publications and expert insights.

Main Results:

CAR T-cell therapy shows promise but faces significant hurdles.
Barriers include manufacturing complexities, cost, and patient accessibility.
Regulatory and clinical integration challenges specific to Korea are identified.

Conclusions:

Effective implementation of CAR T-cell therapy in Korea requires addressing key challenges.
Overcoming these barriers is crucial for maximizing the potential of this immunotherapy.
Further research and strategic planning are needed to advance CAR T-cell therapy in the region.